EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSAPEG00000014270
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSAPEG00000005702
Gene Symbol: CHRM3
1 Cross references
188 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSAPEG00000008958
Gene Symbol: CHRM4
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSAPEG00000008674
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSAPEG00000003466
Gene Symbol: CHRNB2
1 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSAPEG00000008570
Gene Symbol: CHRNB4
1 Cross references
194 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSAPEG00000020661
Gene Symbol: CHRM2A
1 Cross references
196 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSAPEG00000001557
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSAPEG00000007594
Gene Symbol: CHRM5B
1 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSAPEG00000006594
Gene Symbol: CHRNA4B
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSAPEG00000003572
Gene Symbol: CHRNA7A
1 Cross references
208 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor 2.1

Ensembl ID : ENSAPEG00000004248
Gene Symbol: F2R2.1
1 Cross references
265 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).